MBX Biosciences is trading 4.55% lower at $54.33, amid pressure on biotech stocks as Treasury yields rose above 5.3%. - Investors were awaiting Federal Reserve minutes, and broader market weakness was also reported. - No new company-specific announcement or catalyst explaining the October 7 decline surfaced in available search results; recent coverage involved earlier clinical-trial and analyst news, not a clear cause.